EGFR and cancer: Higher YAP expression was implicated in resistance to a number of cancer drugs (20, 21) including the first- and second-generation EGFR-TKIs (22), and treatment of lung cancer with growth factor (vascular endothelial growth factor (VEGF) and YAP) inhibitors provided promising results in previous studies (3, 23).